Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
INKplant is an Austrian medical technology company specializing in the development of personalized, 3D-printed bioresorbable implants for regenerative medicine. Utilizing high-resolution lithography-based ceramic manufacturing (LCM), the company creates scaffolds that mimic the natural structure of bone and cartilage to promote tissue regeneration. These implants are designed to be gradually resorbed by the body, eventually leaving only natural tissue and eliminating the need for permanent metal or plastic prosthetics. INKplant focuses on complex clinical applications, including cleft palate repairs, orbital floor reconstructions, and chronic joint defects. The company coordinates a large-scale European consortium aimed at standardizing and scaling personalized regenerative therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on INKplant.